PMS2 and colorectal cancer: We include both probands with a pathogenic variant in BRCA1, BRCA2, PALB2, MLH1, MSH2, MSH6, or PMS2 and probands with pedigree-based estimation of hereditary risk for breast and colorectal cancer.